Coherus Biosciences, INC

Coherus Oncology, Inc. announced on June 12, 2026, the dismissal of Ernst & Young LLP and the appointment of PricewaterhouseCoopers LLP as its new independent registered public accounting firm.

Coherus Oncology's 2026 Annual Meeting saw director elections and compensation approval, with a partial adjournment for a stock option repricing vote.

Coherus Oncology reported Q1 2026 financial results, with LOQTORZI net revenue reaching $11.8 million, alongside updates on clinical trial progress for tagmokitug and casdozokitug.

Coherus Oncology, Inc. announced a clinical supply agreement with Janssen to evaluate tagmokitug in a Phase 1b study for metastatic castration-resistant prostate cancer.

Coherus Oncology, Inc. has filed a prospectus supplement to allow for the potential sale of up to $64.88 million in common stock through an existing sales agreement.

Coherus Oncology, Inc. reported preliminary unaudited net revenues for Q4 and full year 2025, along with cash position, and projected significant growth for its LOQTORZI product.

Coherus Oncology, Inc. reported first quarter 2026 results, with net revenue from continuing operations increasing to $12.3 million, driven by LOQTORZI sales growth.

Coherus Oncology reports Q3 2025 results, highlighting LOQTORZI revenue growth and the completion of its biosimilar divestiture strategy, alongside ongoing operating losses.

Coherus Oncology, Inc. reported a significant net income driven by the divestiture of its biosimilar businesses, while continuing to advance its immuno-oncology pipeline and commercialize LOQTORZI.

Coherus BioSciences announces its Q1 2025 financial results, highlighting the completion of the UDENYCA divestiture and a strategic focus on its immuno-oncology pipeline.

Coherus BioSciences reports a net income of $79.2 million for the nine months ended September 30, 2024, driven by gains from asset sales, but faces a temporary supply interruption for UDENYCA.

Coherus BioSciences reports a net income of $89.954 million for the six months ended June 30, 2024, driven by strategic asset sales and growth in UDENYCA sales, while also completing debt refinancing.

Coherus BioSciences reports 2024 financials and outlines strategic focus on immuno-oncology following planned UDENYCA divestiture.

Surface Oncology has granted exclusive worldwide rights to GSK to develop and commercialize a novel immunotherapy, SRF813, targeting the inhibitory receptor CD112R.

Director Ali J. Satvat received 30,000 restricted stock units and 60,000 stock options as part of annual compensation for service on the board.

Director Rita A. Karachun was granted 30,000 restricted stock units and 60,000 stock options by Coherus Oncology, Inc.

Coherus Oncology director Lee Nisley Newcomer was granted 30,000 restricted stock units and 60,000 stock options.

Director Michael Lee Ryan was granted 30,000 restricted stock units and 60,000 stock options by Coherus Oncology, Inc.

Director Jill O'Donnell-Tormey was granted 30,000 restricted stock units and 60,000 stock options by Coherus Oncology.

Coherus BioSciences director Mats Wahlstrom was granted 30,000 restricted stock units and 60,000 stock options.

Coherus Oncology announces its 2026 Annual Meeting of Stockholders, detailing proposals including director elections, auditor ratification, executive compensation advisory vote, stock option repricing, and equity plan expansion.

Coherus BioSciences announces its 2025 Annual Meeting of Stockholders to be held on June 11, 2025, outlining key proposals for voting, including the election of directors, ratification of the auditor, executive compensation approval, and an amendment to the employee stock purchase plan.

Coherus BioSciences is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the selection of its auditor, approve executive compensation, and amend its Employee Stock Purchase Plan.

Coherus BioSciences provides supplemental disclosures regarding the proposed sale of its UDENYCA franchise to Intas Pharmaceuticals in response to stockholder demand letters and lawsuits.

Coherus BioSciences plans to divest its UDENYCA franchise to Intas Pharmaceuticals for up to $558.4 million to strengthen its financial position and focus on its innovative oncology portfolio.

Coherus BioSciences is set to sell its UDENYCA business to Intas Pharmaceuticals for $483.4 million in cash, plus potential earnout payments, as part of a strategic shift towards immuno-oncology.

Timothy G. Youngquist 2020 Irrevocable Trust reports 8.3% stake in Coherus Oncology, Inc. as of March 31, 2026.

The Timothy G. Youngquist 2020 Irrevocable Trust has reported beneficial ownership of 8.267% of Coherus Oncology, Inc. common stock.

Thomas A. Satterfield, Jr. filed a Schedule 13G reporting a 4.6% beneficial ownership stake in Coherus Oncology, Inc.

The Vanguard Group reports 0% beneficial ownership of Coherus Oncology Inc. common stock following an internal corporate realignment.

The Timothy G. Youngquist 2020 Irrevocable Trust has reported a 6.49% beneficial ownership stake in Coherus Oncology, Inc., primarily for investment purposes.

The Vanguard Group has reported an 8.29% beneficial ownership stake in Coherus Oncology Inc., holding over 10 million shares as of December 31, 2025.